Latest Insurance News

Barramundi’s portfolio returned a solid 3.8% gross gain in Q2 2026, driven by strong AI-related infrastructure plays and takeover interest in key holdings, despite sector volatility and profit downgrades in healthcare and logistics.

Income Asset Management Group (ASX:IAM) closed FY2026 Q4 with a record $2.12 billion in trade turnover and resolved key fraud and litigation matters, while its Managed Discretionary Account grew to $23 million.

Phoslock Environmental Technologies increased production significantly in the June quarter but faced a higher operating cash flow deficit and ongoing legal disputes.

Lithium Universe (ASX: LU7) reports strong construction progress at Norah Mining's Nigerian spodumene concentrator, securing long-term feedstock and opening interim trading opportunities ahead of its North American refinery launches.

Steadfast Group confirms Kohlberg Kravis Roberts has joined the consortium bidding to acquire the company at $6 per share, with no change to the transaction timeline or terms.

FlexiRoam has inked a non-binding MoU with a major global telecommunications player to jointly pursue enterprise and MVNO opportunities using its AI-powered eSIM platform, marking a strategic channel expansion.

Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.

Skellerup has raised its FY26 net profit after tax forecast to $64-$65 million, driven by robust demand in the US and New Zealand markets, improved supply chain conditions, and favourable currency and tariff impacts.

Bridge SaaS Limited has exited its non-core investment in Brightside Disability Support, recouping its initial outlay and sharpening its focus on AI-driven disability services and robotics innovation.

INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.

Steadfast Group has granted a four-week extension to the exclusivity period for its non-binding $6 per share acquisition proposal from a consortium led by Amwins and Dragoneer, following their re-confirmation to proceed.

FDC Consolidated lifted its profit after tax to $54.9 million for FY2025, alongside a significant jump in dividends paid and a strong revenue increase driven by its construction and fitout operations across Australia.